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Abstract
There	 is	compelling	evidence	 to	support	 the	quality,	
cost	effectiveness	and	safety	profile	of	non-anesthe-
siologist-administered	propofol	 for	endoscopic	ultra-
sound	 (EUS).	However	 in	 the	United	Kingdom,	 it	 is	
recommended	that	 the	administration	and	monitoring	
of	propofol	sedation	for	endoscopic	procedures	should	
be	the	responsibility	of	a	dedicated	and	appropriately	
trained	 anaesthetist	 only.	 The	majority	 of	United	
Kingdom	EUS	procedures	are	performed	with	opiate	
and	benzodiazepine	sedation	rather	than	anaesthetist	
led	propofol	 lists	due	 to	anaesthetist	 resource	avail-
ability.	We	 sought	 to	 prospectively	 determine	 the	
tolerability	 and	 safety	of	 EUS	with	benzodiazepine	
and	opiate	sedation	 in	single	United	Kingdom	centre.	
Two	hundred	consecutive	patients	undergoing	either	
EUS	or	oesophago-gastroduodenoscopy	 (OGD)	with	
conscious	sedation	were	prospectively	recruited	with	a	
1:1	enrolment	ratio.	Patients	completed	questionnaires	
pre	and	post	procedure	detailing	anticipated	and	actual	
pain	experienced	on	a	1-10	visual	 analogue	 scale.	
Demographics,	procedure	duration,	sedation	doses	and	
willingness	to	repeat	the	procedure	were	also	recorded.	
EUS	procedures	 lasted	significantly	 longer	than	OGDs	
(15	min	vs 	6	min,	P 	<	0.0001),	however,	 there	was	
no	difference	 in	anticipated	pain	scores	between	the	
groups	(EUS	3.37/10	vs 	OGD	3.47/10,	P 	=	0.46).	Pain	
scores	 indicated	EUS	was	better	 tolerated	 than	OGD	
(1.16/10	vs 	1.88/10,	P 	=	0.03)	although	higher	doses	
of	sedation	were	used	for	EUS	procedures.	There	were	
no	complications	identified	in	either	group.	We	feel	our	
study	demonstrates	 that	 the	 tolerability	of	EUS	with	
opiate	and	benzodiazepine	sedation	is	acceptable.
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Core tip: Strong	evidence	exists	 to	 support	 safety	
and	tolerability	of	non-anaesthesiologist-administered	
propofol	 for	endoscopic	ultrasound	(EUS)	procedures.	
United	Kingdom	guidelines,	 however,	 recommend	
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propofol	 is	administered	only	by	anaesthesiologists.	
Consequently,	 in	 the	 United	 Kingdom,	 nearly	 all	
EUS	procedures	are	performed	with	combinations	of	
benzodiazepine	and	opiate	 sedation	 for	which	 little	
tolerability	data	exists.	This	letter	shares	the	experience	
of	a	single	EUS	centre	using	benzodiazepine	and	opiate	
sedation	demonstrating	it	can	be	safe	and	the	resulting	
tolerability	acceptable.
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TO THE EDITOR
We read with interest the review by Cheriyan and 
Byrne analysing the benefits of propofol sedation in 
advanced endoscopic procedures and endoscopic 
ultrasound (EUS)[1]. Whilst we agree that there is 
compelling evidence to support the quality, cost effec-
tiveness and safety profile of non-anaesthesiologist-
administered propofol (NAAP) for EUS (including 
gastroenterologist and nurse administration)[1-3], there 
are current restrictions in the United Kingdom which 
make NAAP difficult to implement for all EUS proce-
dures. Propofol can produce transient apnoea or gen-
eral anaesthesia for which there is no reversal agent, 
therefore the United Kingdom joint anaesthetic and 
gastroenterology guidelines recommend that propofol 
administration for complex endoscopic procedures 
should be the responsibility of dedicated anaesthetists 
only[4]. Demand for EUS in the United Kingdom is 
increasing and as a consequence, it is not feasible for 
all EUS procedures to be performed with anaesthesi-
ologist administration. The vast majority are carried 
out using combination opiate and benzodiazepine 
sedation. Although a number of studies have sought to 
assess tolerability of gastroscopy and colonoscopy with 
benzodiazepine and opiate sedation[5-7] this has rarely 
included EUS[8,9]. EUS procedures take longer and use 
larger diameter endoscopes (13.8-14.6 mm) com-
pared to conventional oesophago-gastroduodenoscopy 
(OGD) (9.9-10.2 mm). It is important to ensure that 
EUS tolerability is acceptable. We prospectively exam-
ined outcomes in a single EUS centre in the United 
Kingdom to assess if the tolerability of sedated EUS 
was comparable to sedated OGD.
Consecutive patients undergoing EUS or OGD with 
sedation (either midazolam and or fentanyl) were pro-
spectively identified with a 1:1 enrolment ratio. After 
being counselled and consented, patients were asked 
to complete pre and post procedure questionnaires. 
A visual analogue scale (0-10) was used to record 
patients’ expected pain pre-procedure and the actual 
pain perceived post-procedure. Subsequent willingness 
to repeat the procedure was also noted. Procedure 
duration and sedation dosages were recorded for 
each patient. Sedation complications were regarded 
as use of intravenous reversal agents and or assisted 
ventilation. Fisher’s test was used to generate P values 
comparing the means of groups for age, duration, 
drug doses and pain scores. Unpaired t-test was used 
to calculate P values for willingness to have a repeat 
procedure.
Two hundred consecutive patients undergoing 
either OGD (100) or EUS (100) were recruited (Table 
1). All procedures were completed and no significant 
difference in expected pain scores between the OGD 
and EUS groups were observed (P = 0.46). EUS pro-
cedures lasted significantly longer than OGDs (15 min 
vs 6 min, P < 0.0001) and used significantly higher 
doses of both midazolam (P = 0.001) and fentanyl 
(P < 0.0001). Patients undergoing EUS were signifi-
cantly more likely to receive fentanyl and midazolam 
in combination compared to those having ODG (67% 
vs 6%, P < 0.0001). Despite the increased procedure 
time in the EUS group, the sedation used resulted in 
significantly lower pain scores for EUS compared to 
OGD (1.16/10 vs 1.88/10, P = 0.03). Assisted venti-
lation was not required and no intravenous sedation 
reversal agents were used in either group.
In conclusion, although propofol has been shown 
to be a superior sedation agent the mandatory anaes-
thetic support required in the United Kingdom makes 
its unfeasible to be used for all EUS procedures. We 
feel our study demonstrates that the tolerability of EUS 
with opiate and benzodiazepine sedation is acceptable.
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